These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 9279722)

  • 1. Early appearance of neutralizing antibodies after vaccination with an inactivated hepatitis A vaccine.
    Flehmig B; Staedele H; Xueref C; Vidor E; Zuckerman J; Zuckerman A
    J Infect; 1997 Jul; 35(1):37-40. PubMed ID: 9279722
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Analysis of the antibody response in humans with a new inactivated hepatitis A vaccine.
    Vidor E; Xueref C; Blondeau C; Bajard A; Francon A; Goudeau A; Peyron F; Brasseur P; Zuckerman A
    Biologicals; 1996 Sep; 24(3):235-42. PubMed ID: 8978923
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Inactivated hepatitis A vaccine: reactogenicity, immunogenicity, and long-term antibody persistence.
    Van Damme P; Thoelen S; Cramm M; De Groote K; Safary A; Meheus A
    J Med Virol; 1994 Dec; 44(4):446-51. PubMed ID: 7897379
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Single and booster dose responses to an inactivated hepatitis A virus vaccine: comparison with immune serum globulin prophylaxis.
    Shouval D; Ashur Y; Adler R; Lewis JA; Armstrong ME; Davide JP; McGuire B; Kuter B; Brown L; Miller W
    Vaccine; 1993; 11 Suppl 1():S9-14. PubMed ID: 8383390
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Immunogenicity and safety of a new inactivated hepatitis A vaccine in a comparative study.
    Goilav C; Zuckerman J; Lafrenz M; Vidor E; Lauwers S; Ratheau C; Benichou G; Zuckerman A
    J Med Virol; 1995 Jul; 46(3):287-92. PubMed ID: 7561805
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Comparison of two immunization schedules with an inactivated hepatitis A vaccine (AvaximTM).
    Vidor E; Ratheau C; Briantais P; Vuillier D
    J Travel Med; 1998 Dec; 5(4):167-72. PubMed ID: 9876189
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rapid antibody response after vaccination with a virosomal hepatitis a vaccine.
    Ambrosch F; Finkel B; Herzog C; Koren A; Kollaritsch H
    Infection; 2004 Jun; 32(3):149-52. PubMed ID: 15188074
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Clinical experience with an inactivated hepatitis A vaccine.
    Clemens R; Safary A; Hepburn A; Roche C; Stanbury WJ; André FE
    J Infect Dis; 1995 Mar; 171 Suppl 1():S44-9. PubMed ID: 7876648
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Immunization of US soldiers with a two-dose primary series of inactivated hepatitis A vaccine: early immune response, persistence of antibody, and response to a third dose at 1 year.
    DeFraites RF; Feighner BH; Binn LN; Kanjarpane DD; Delem AD; MacArthy PO; Krauss MR; Krause DS; Moonsammy GI; Hoke CH
    J Infect Dis; 1995 Mar; 171 Suppl 1():S61-9. PubMed ID: 7876651
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Safety, immunogenicity and antibody persistence of an inactivated hepatitis A vaccine in 4 to 15 year old children.
    Castillo de Febres O; Chacon de Petrola M; Casanova de Escalona L; Naveda O; Naveda M; Estopinan M; Bordones G; Zambrano B; Garcia A; Dumas R
    Vaccine; 1999 Nov; 18(7-8):656-64. PubMed ID: 10547425
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Cell mediated and antibody immune response to inactivated hepatitis A vaccine.
    Schmidtke P; Habermehl P; Knuf M; Meyer CU; Sänger R; Zepp F
    Vaccine; 2005 Oct; 23(44):5127-32. PubMed ID: 16054733
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Immunogenicity and reactogenicity of Avaxim (160 AU) as compared with Havrix (1440 EL.U) as a booster following primary immunization with Havrix (1440 EL.U) against hepatitis A.
    Zuckerman JN; Kirkpatrick CT; Huang M
    J Travel Med; 1998 Mar; 5(1):18-22. PubMed ID: 9772311
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Characterization of the immune response of volunteers vaccinated with a killed vaccine against hepatitis A.
    Delem A; Safary A; De Namur F; Hauser P; D'Hondt E
    Vaccine; 1993; 11(4):479-84. PubMed ID: 8385844
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Inactivated virosome hepatitis A vaccine.
    Loutan L; Bovier P; Althaus B; Glück R
    Lancet; 1994 Feb; 343(8893):322-4. PubMed ID: 7905144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Hepatitis A vaccination by intracutaneous low dose administration: a less expensive alternative.
    Carlsson U; Brudin L; Eliasson I; Hansson BG
    Scand J Infect Dis; 1996; 28(5):435-8. PubMed ID: 8953668
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Single dose inactivated hepatitis A vaccine: rationale and clinical assessment of the safety and immunogenicity.
    Van Damme P; Matheï C; Thoelen S; Meheus A; Safary A; André FE
    J Med Virol; 1994 Dec; 44(4):435-41. PubMed ID: 7897376
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Hepatitis A vaccine: which dose is best?
    Lonergan G
    JAMA; 1995 Apr; 273(13):999-1000. PubMed ID: 7897815
    [No Abstract]   [Full Text] [Related]  

  • 18. Mathematical models for assessment of long-term persistence of antibodies after vaccination with two inactivated hepatitis A vaccines.
    Van Herck K; Beutels P; Van Damme P; Beutels M; Van den Dries J; Briantais P; Vidor E
    J Med Virol; 2000 Jan; 60(1):1-7. PubMed ID: 10568755
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Hepatitis A vaccine.
    Med Lett Drugs Ther; 1995 Jun; 37(950):51-2. PubMed ID: 7760768
    [No Abstract]   [Full Text] [Related]  

  • 20. Hepatitis A vaccine. A new convenient single-dose schedule with booster when long-term immunization is warranted.
    Victor J; Knudsen JD; Nielsen LP; Fomsgaard A; Thybo S; Bygbjerg I; Westh H
    Vaccine; 1994 Nov; 12(14):1327-9. PubMed ID: 7856299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.